Application 210491

Type
NDA
Sponsor
VERTEX PHARMS INC

Related Records

Application Products

ProductDrugIngredientFormStrengthReference drugReference standard
001SYMDEKO (COPACKAGED)IVACAFTOR; IVACAFTOR, TEZACAFTORTABLET, TABLET;ORAL150MG,N/A;150MG, 100MGYesYes
002SYMDEKO (COPACKAGED)IVACAFTOR; IVACAFTOR, TEZACAFTORTABLET, TABLET;ORAL75MG,N/A;75MG, 50MGYesNo

NDC Listings For This Application

NDCNameNonproprietary nameLabelerMarketing categoryStatus
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-113SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent
51167-661SYMDEKOTezacaftor and IvacaftorVertex Pharmaceuticals IncorporatedNDACurrent

Documents

DocumentSubmission typeDate
85469SUPPL 2026-03-24
83568SUPPL 2025-09-26
83540SUPPL 2025-09-26
74996SUPPL 2023-08-04
65744SUPPL2020-12-28
65710SUPPL2020-12-23
61505SUPPL2020-01-02
61470SUPPL2019-12-30
59177SUPPL2019-06-27
59163SUPPL2019-06-24
52945ORIG2018-03-13
52602ORIG2018-02-13
52601ORIG2018-02-13